作者
Sima Singh, Arshid Numan, Balaji Maddiboyina, Saahil Arora, Yassine Riadi, Shadab Md, Nabil A Alhakamy, Prashant Kesharwani
发表日期
2021/7/1
来源
Drug discovery today
卷号
26
期号
7
页码范围
1721-1727
出版商
Elsevier Current Trends
简介
Highlights
- TNBCs is one of the most heterogenous form of breast cancer appear to have elevated numbers of immune cells infiltration.
- Using immune checkpoint inhibitors (ICIs) based treatment will help to identify novel effective therapies against TNBC.
- The effectiveness of ICI treatments for TNBC is confirmed by clinical evidence.
Triple-negative breast cancers (TNBCs) form a heterogeneous group of breast carcinomas that lack expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. In the past decade, immune checkpoint inhibitors (ICIs) have revolutionized the arena of cancer immunotherapy. Early results are now accumulating from trials involving the treatment of TNBCs with radical ICIs therapies, including combinational therapies that include ICI technologies. In this review, we provide a broad overview of the progress of immunotherapy-based treatments and discuss …
学术搜索中的文章
S Singh, A Numan, B Maddiboyina, S Arora, Y Riadi… - Drug discovery today, 2021